FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288032596> ?p ?o ?g. }

• W4288032596 endingPage "113433" @default.
• W4288032596 startingPage "113433" @default.
• W4288032596 abstract "Lupus nephritis (LN) is the most common complication of systemic lupus erythematosus (SLE), and the abnormal activation of the alternative complement pathway is associated with the pathogenesis of LN. As an inhibitor of complement factor B (CFB) in the alternative pathway, LNP023 has been used in the treatment of a variety of renal diseases with abnormal complement system involvement, such as paroxysmal nocturnal hemoglobinuria, IgA nephropathy, and membranous nephropathy. The aim of our study was to explore whether LNP023 improved LN in MRL/lpr mice by inhibiting the activation of the alternative complement pathway.The mice were divided into a normal control group (Normal group) (n = 6), MRL/lpr model group (n = 6), and LNP023 group (n = 6). The LNP023 group was administered LNP023 for 2 weeks by gavage; the MRL/lpr model group was administered saline for 2 weeks by gavage; and the Normal group was administered saline for 2 weeks by gavage. External signs, renal pathology, renal function, renal immune complex and complement deposition, serum anti-dsDNA, serum ANA concentration, and the expression of core complement factors in the alternative complement pathway were analyzed in the 3 groups of animals. The core targets of LNP023 in the treatment of LN were screened using network pharmacology. The pathogenicity of the core targets in LN was verified by analyzing the mRNA expression of the core targets in the peripheral blood mononuclear cells (PBMCs) of normal individuals, SLE patients, and LN patients. The mRNA and protein expression of core targets in the Normal group, MRL/lpr group, and LNP023 group were analyzed to verify whether LNP023 exerted it LN therapeutic effect through the regulation of core targets.Compared with the MRL/lpr group, the LNP023 group had reduced lupus-like signs, improved renal function, decreased serum anti-dsDNA and ANA concentrations, and reduced renal IgM, IgG, IgG1, C1q, C3, and C4 deposition. Renal pathology showed that LNP023 attenuated pathological damage in the kidneys of MRL/lpr mice. Compared with the MRL/lpr model group, the treatment group had no crescent formation, less immune deposition, no nuclear fragmentation, and less inflammatory cell infiltration. The expression of complement proteins C3, C3b, CR1, CFB, and C5b-9 in kidney tissues and liver was decreased, and the expression of C5 was increased. Network pharmacology screening indicated that AKT, TNF-α, MDM2, UBC, STST3, ESR1, and TP53 were core targets of LNP023 in the treatment of LN. Compared with that in the Normal group, the mRNA expression of the core target in the SLE and LN groups was different; compared with the MRL/lpr group, the LNP023 treatment group showed different mRNA and protein expression levels of AKT, TNF-α, and STST3.LNP023 improves LN in MRL/lpr mice. The mechanism is as follows: LNP023 binds to CFB to inhibit the activation of the alternative complement pathway. LNP023 treatment for LN may also play a role in regulating the protein expression of AKT, TNF-α, and STST3." @default.
• W4288032596 created "2022-07-27" @default.
• W4288032596 creator A5025392425 @default.
• W4288032596 creator A5050579675 @default.
• W4288032596 creator A5053590867 @default.
• W4288032596 creator A5060135800 @default.
• W4288032596 creator A5068613488 @default.
• W4288032596 creator A5071636027 @default.
• W4288032596 creator A5071950931 @default.
• W4288032596 date "2022-09-01" @default.
• W4288032596 modified "2023-10-17" @default.
• W4288032596 title "Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice" @default.
• W4288032596 cites W121687570 @default.
• W4288032596 cites W1917304705 @default.
• W4288032596 cites W1945739033 @default.
• W4288032596 cites W1990568953 @default.
• W4288032596 cites W2008158047 @default.
• W4288032596 cites W2008164097 @default.
• W4288032596 cites W2041326076 @default.
• W4288032596 cites W2042029544 @default.
• W4288032596 cites W2048538843 @default.
• W4288032596 cites W2067217824 @default.
• W4288032596 cites W2070485926 @default.
• W4288032596 cites W2125033229 @default.
• W4288032596 cites W2128723871 @default.
• W4288032596 cites W2156890640 @default.
• W4288032596 cites W2160382588 @default.
• W4288032596 cites W2272550089 @default.
• W4288032596 cites W2414418869 @default.
• W4288032596 cites W2465446350 @default.
• W4288032596 cites W2474747771 @default.
• W4288032596 cites W2720897370 @default.
• W4288032596 cites W2911087907 @default.
• W4288032596 cites W2927939151 @default.
• W4288032596 cites W2928665623 @default.
• W4288032596 cites W2994389446 @default.
• W4288032596 cites W3083181989 @default.
• W4288032596 cites W3097145107 @default.
• W4288032596 cites W315197452 @default.
• W4288032596 cites W4255287828 @default.
• W4288032596 cites W4313341453 @default.
• W4288032596 doi "https://doi.org/10.1016/j.biopha.2022.113433" @default.
• W4288032596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36076550" @default.
• W4288032596 hasPublicationYear "2022" @default.
• W4288032596 type Work @default.
• W4288032596 citedByCount "6" @default.
• W4288032596 countsByYear W42880325962022 @default.
• W4288032596 countsByYear W42880325962023 @default.
• W4288032596 crossrefType "journal-article" @default.
• W4288032596 hasAuthorship W4288032596A5025392425 @default.
• W4288032596 hasAuthorship W4288032596A5050579675 @default.
• W4288032596 hasAuthorship W4288032596A5053590867 @default.
• W4288032596 hasAuthorship W4288032596A5060135800 @default.
• W4288032596 hasAuthorship W4288032596A5068613488 @default.
• W4288032596 hasAuthorship W4288032596A5071636027 @default.
• W4288032596 hasAuthorship W4288032596A5071950931 @default.
• W4288032596 hasBestOaLocation W42880325961 @default.
• W4288032596 hasConcept C111684460 @default.
• W4288032596 hasConcept C126322002 @default.
• W4288032596 hasConcept C134018914 @default.
• W4288032596 hasConcept C159654299 @default.
• W4288032596 hasConcept C182629451 @default.
• W4288032596 hasConcept C189446657 @default.
• W4288032596 hasConcept C203014093 @default.
• W4288032596 hasConcept C2776912625 @default.
• W4288032596 hasConcept C2779134260 @default.
• W4288032596 hasConcept C2779703309 @default.
• W4288032596 hasConcept C2779912601 @default.
• W4288032596 hasConcept C2780942790 @default.
• W4288032596 hasConcept C2781184683 @default.
• W4288032596 hasConcept C555293320 @default.
• W4288032596 hasConcept C71924100 @default.
• W4288032596 hasConcept C8891405 @default.
• W4288032596 hasConceptScore W4288032596C111684460 @default.
• W4288032596 hasConceptScore W4288032596C126322002 @default.
• W4288032596 hasConceptScore W4288032596C134018914 @default.
• W4288032596 hasConceptScore W4288032596C159654299 @default.
• W4288032596 hasConceptScore W4288032596C182629451 @default.
• W4288032596 hasConceptScore W4288032596C189446657 @default.
• W4288032596 hasConceptScore W4288032596C203014093 @default.
• W4288032596 hasConceptScore W4288032596C2776912625 @default.
• W4288032596 hasConceptScore W4288032596C2779134260 @default.
• W4288032596 hasConceptScore W4288032596C2779703309 @default.
• W4288032596 hasConceptScore W4288032596C2779912601 @default.
• W4288032596 hasConceptScore W4288032596C2780942790 @default.
• W4288032596 hasConceptScore W4288032596C2781184683 @default.
• W4288032596 hasConceptScore W4288032596C555293320 @default.
• W4288032596 hasConceptScore W4288032596C71924100 @default.
• W4288032596 hasConceptScore W4288032596C8891405 @default.
• W4288032596 hasLocation W42880325961 @default.
• W4288032596 hasLocation W42880325962 @default.
• W4288032596 hasOpenAccess W4288032596 @default.
• W4288032596 hasPrimaryLocation W42880325961 @default.
• W4288032596 hasRelatedWork W1140975575 @default.
• W4288032596 hasRelatedWork W1554414803 @default.
• W4288032596 hasRelatedWork W1945739033 @default.
• W4288032596 hasRelatedWork W1971239693 @default.
• W4288032596 hasRelatedWork W1995877687 @default.

• next